Hepatocellular carcinoma: an epidemiologic view
- PMID: 12394209
- DOI: 10.1097/00004836-200211002-00002
Hepatocellular carcinoma: an epidemiologic view
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and is estimated to cause approximately half a million deaths annually. Because of its high fatality rates, the incidence and mortality rates are almost equal. The major risk factors for HCC are chronic hepatitis B virus infection, chronic hepatitis C virus (HCV) infection, and alcoholic cirrhosis. The epidemiology of HCC is characterized by marked demographic (age, gender, race/ethnicity) and geographic variations. Hepatitis B virus infection, with and without aflatoxin exposure, is responsible for most cases in developing countries; better control of these risk factors has resulted in a recent decline in HCC in some places like Taiwan and China. Recently, however, a trend of rising rates of HCC has been reported from several developed countries in Europe and North America. These new trends are associated with "new" risk factors such as HCV and, possibly, diabetes. In the United States, the incidence of HCC has approximately doubled over the past 3 decades. White individuals are two to three times less often affected than African Americans, who in turn are two to three times less often affected than Asians, Pacific Islanders, or Native Americans. Men are two to three times more often affected than women. Concomitant with the rising rates of HCC, there has been a shift of incidence from typically elderly patients to relatively younger patients between ages of 40 to 60 years. An increase in HCV-related HCC accounts for at least half of the witnessed increase in HCC in the United States. Hepatocellular carcinoma continues to carry an overall dismal survival rate (close to 5%); very few patients qualify for and receive potentially curative therapy. The future incidence trends of HCC will be determined to a large extent by the clinical course of HCV-infected people.
Similar articles
-
Hepatocellular carcinoma: recent trends in the United States.Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34. doi: 10.1053/j.gastro.2004.09.013. Gastroenterology. 2004. PMID: 15508094 Review.
-
Hepatocellular carcinoma, a rapidly increasing public health problem: the Tulane experience 2003-2009.J La State Med Soc. 2011 Jul-Aug;163(4):185-90. J La State Med Soc. 2011. PMID: 21954650
-
The epidemiology and prevention of hepatocellular carcinoma.Semin Oncol. 2001 Oct;28(5):441-9. doi: 10.1016/s0093-7754(01)90137-x. Semin Oncol. 2001. PMID: 11685737 Review.
-
Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2017 Dec;46(11-12):1061-1069. doi: 10.1111/apt.14342. Epub 2017 Sep 28. Aliment Pharmacol Ther. 2017. PMID: 28960360
-
Global trends and predictions in hepatocellular carcinoma mortality.J Hepatol. 2017 Aug;67(2):302-309. doi: 10.1016/j.jhep.2017.03.011. Epub 2017 Mar 21. J Hepatol. 2017. PMID: 28336466
Cited by
-
RNAa-mediated overexpression of WT1 induces apoptosis in HepG2 cells.World J Surg Oncol. 2012 Jan 13;10:11. doi: 10.1186/1477-7819-10-11. World J Surg Oncol. 2012. PMID: 22244202 Free PMC article.
-
Antitumor activity of type I and type III interferons in BNL hepatoma model.Cancer Immunol Immunother. 2010 Jul;59(7):1059-71. doi: 10.1007/s00262-010-0831-3. Epub 2010 Mar 9. Cancer Immunol Immunother. 2010. PMID: 20217081 Free PMC article.
-
Evaluation of interleukin 8 polymorphisms (-251T/A and +781C/T) in patients with hepatocellular carcinoma: a meta-analysis.Clin Exp Hepatol. 2021 Sep;7(3):278-285. doi: 10.5114/ceh.2021.109424. Epub 2021 Oct 12. Clin Exp Hepatol. 2021. PMID: 34712829 Free PMC article.
-
Clinicopathological features and outcomes of young patients with hepatocellular carcinoma after hepatectomy.World J Surg. 2011 May;35(5):1063-71. doi: 10.1007/s00268-011-1017-7. World J Surg. 2011. PMID: 21380583
-
Liver transplantation, liver resection, and transarterial chemoembolization for hepatocellular carcinoma in cirrhosis: which is the best oncological approach?Dig Dis Sci. 2009 Oct;54(10):2264-73. doi: 10.1007/s10620-008-0604-4. Epub 2008 Dec 5. Dig Dis Sci. 2009. PMID: 19057997
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous